AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27039986 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 4.5 g TID
Number of subjects: 60
Study 27039986 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 4.5 g BID
Number of subjects: 60
Study 27039986 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 60
Study 27040099 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonradiation EUS-based ERCP
Number of subjects: 31
Study 27040320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralatrexate (10 to 30 mg/m²) + Bortezomib (1.3 mg/m²)
Number of subjects: 11
Study 27040320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralatrexate + Bortezomib
Number of subjects: 11
Study 27041409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (PLX3397) in a Phase III clinical trial
Number of subjects: 22
Study 27041409 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst pain numeric rating scale
Number of subjects: 22
Study 27041409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcomes Measurement Information System physical functioning items
Number of subjects: 22
Study 27041409 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Ontario and McMaster Universities Osteoarthritis Index
Number of subjects: 22
Study 27041409 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst stiffness numeric rating scale developed for TGCT
Number of subjects: 22
Study 27042048 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotyping patients with COPD in a real-life setting
Number of subjects: 84
Study 27042048 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of differences in symptoms and therapeutic behavior
Number of subjects: 84
Study 27042163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily (first dose 110 mg 1-4 h after surgery)
Number of subjects: 5292
Study 27042281 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 22
Study 27042281 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 22
Study 27042285 — intervention group
Group type: EXPERIMENTAL
Intervention: Copy number variations (CNVs) affecting PARK2 gene
Number of subjects: 335
Study 27042285 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD cases with exonic duplication of PARK2
Number of subjects: 335
Study 27042285 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 335
Study 27042312 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (85-90% of 1 repetition maximum (1RM)) 3 times a week for 8 weeks
Number of subjects: 24
Study 27042312 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical activities
Number of subjects: 24
Study 27042326 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid-femoral pulse wave velocity (cf-PWV) measurement
Number of subjects: 15
Study 27042326 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation index (AIx@HR75) measurement
Number of subjects: 15
Study 27042326 — intervention group
Group type: EXPERIMENTAL
Intervention: Central pulse pressure (CPP) measurement
Number of subjects: 15
Study 27042326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-class correlation coefficients (ICCs) for reproducibility
Number of subjects: 15
Study 27042326 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard vs direct method for distance measurement
Number of subjects: 15
Study 27042326 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient acceptance and comfort survey
Number of subjects: 15
Study 27042336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tender joints
Number of subjects: 59
Study 27042336 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovitis (clinical assessment)
Number of subjects: 59
Study 27042336 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovitis (PDUS assessment)
Number of subjects: 59
Study 27042336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tender joints with synovitis
Number of subjects: 59
Study 27042336 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-tender joints with no synovitis
Number of subjects: 59
Study 27042336 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of tender joints
Number of subjects: 59
Study 27042336 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence of synovitis
Number of subjects: 59
Study 27042677 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 27042677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27042931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance after 5 and 10 years
Number of subjects: 27450
Study 27042931 — intervention group
Group type: COMPARATOR
Intervention: Surveillance after 10 years only
Number of subjects: 27450
Study 27042931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance after 3, 5, and 10 years
Number of subjects: 27450
Study 27042931 — intervention group
Group type: COMPARATOR
Intervention: Surveillance after 5 and 10 years only
Number of subjects: 27450
Study 27042931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance after 5 and 10 years for patients with serrated polyps ≥10mm or serrated polyps ≥5mm proximal to the splenic flexure
Number of subjects: 27450
Study 27043883 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 2070
Study 27043883 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 2070
Study 27043883 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant-free survival (TFS)
Number of subjects: 2070
Study 27043883 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplantation survival
Number of subjects: 2070
Study 27043883 — intervention group
Group type: COMPARATOR
Intervention: Red blood cell infusions
Number of subjects: 2070
Study 27043883 — intervention group
Group type: COMPARATOR
Intervention: Plasma infusions
Number of subjects: 2070
Study 27043883 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 2070
Study 27043883 — intervention group
Group type: COMPARATOR
Intervention: Vasopressors
Number of subjects: 2070
Study 27044252 — intervention group
Group type: EXPERIMENTAL
Intervention: French cohort
Number of subjects: 120
Study 27044252 — intervention group
Group type: COMPARATOR
Intervention: Australian cohort
Number of subjects: 120
Study 27044310 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation technology with step counter (Fitbit Zip) monitoring for 12 months.
Number of subjects: 64
Study 27044310 — intervention group
Group type: COMPARATOR
Intervention: Telerehabilitation at a call center.
Number of subjects: 64
Study 27044310 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients and those who used the pedometer longer walked significantly more steps (P=.01 and P=.04 respectively).
Number of subjects: 64
Study 27044310 — intervention group
Group type: COMPARATOR
Intervention: Three rehabilitation settings (call center, community health care center, hospital).
Number of subjects: 64
Study 27044576 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium+olodaterol 5/5 µg with exercise training
Number of subjects: 0
Study 27044576 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium+olodaterol 5/5 µg without exercise training
Number of subjects: 0
Study 27044576 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium 5 µg
Number of subjects: 0
Study 27044576 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 27044936 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian function suppression (OFS)
Number of subjects: 4891
Study 27044936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian function suppression (OFS)
Number of subjects: 4891
Study 27044936 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 4891
Study 27044936 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus OFS
Number of subjects: 4891
Study 27044936 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus OFS
Number of subjects: 4891
Study 27044938 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2606368 at 40 mg/m(2) (schedule 1)
Number of subjects: 45
Study 27044938 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2606368 at 105 mg/m(2) (schedule 2)
Number of subjects: 45
Study 27044938 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2606368
Number of subjects: 45
Study 27045102 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-selected clinical trials (ATTACC-companion clinical trials)
Number of subjects: 484
Study 27045102 — intervention group
Group type: COMPARATOR
Intervention: Nonbiomarker selected clinical trials
Number of subjects: 484
Study 27045102 — intervention group
Group type: EXPERIMENTAL
Intervention: Early molecular screening for ATTACC-companion clinical trials
Number of subjects: 484
Study 27045164 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib therapy in AP CML patients
Number of subjects: 140
Study 27045164 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib therapy in BP CML patients
Number of subjects: 140
Study 27045564 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural analgesia
Number of subjects: 495
Study 27045564 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous analgesia
Number of subjects: 495
Study 27045564 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful venipuncture in one attempt
Number of subjects: 495
Study 27045564 — intervention group
Group type: EXPERIMENTAL
Intervention: High pain scores
Number of subjects: 495
Study 27045564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of preprocedural analgesia
Number of subjects: 495
Study 27045862 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum betatrophin levels in patients with NAFLD
Number of subjects: 164
Study 27045862 — intervention group
Group type: COMPARATOR
Intervention: Serum betatrophin levels in controls
Number of subjects: 164
Study 27045862 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of circulating betatrophin with obesity and glycemic indices
Number of subjects: 164
Study 27045862 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance index effect on betatrophin levels
Number of subjects: 164
Study 27045862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic expression of betatrophin in mice with NAFLD
Number of subjects: 164
Study 27046364 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (RYGB or LAGB)
Number of subjects: 2221
Study 27047630 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-focused ultrasound with visualization with vertical vectoring treatment
Number of subjects: 20
Study 27048632 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 303
Study 27048707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 0
Study 27048707 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study 27048835 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination of Lactobacillus rhamnosus GG (LGG) and Bifidobacterium animalis ssp. lactis BB12 (BB12)
Number of subjects: 983
Study 27048835 — intervention group
Group type: COMPARATOR
Intervention: Control chewing tablet
Number of subjects: 983
Study 27048911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40-120 mg once daily
Number of subjects: 251
Study 27049236 — intervention group
Group type: EXPERIMENTAL
Intervention: TGFβ isoforms (TGFβ1 and TGFβ3) stimulation in vitro
Number of subjects: 0
Study 27049236 — intervention group
Group type: EXPERIMENTAL
Intervention: COL4A1 expression in obese subjects
Number of subjects: 0
Study 27049236 — intervention group
Group type: EXPERIMENTAL
Intervention: COL4A1 expression
Number of subjects: 0
Study 27049236 — intervention group
Group type: EXPERIMENTAL
Intervention: TGFβ isoforms (TGFβ1 and TGFβ3) exposure
Number of subjects: 0
Study 27049457 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 once-daily (MTD 60 mg)
Number of subjects: 44
Study 27049457 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 twice-weekly (MTD 150 mg)
Number of subjects: 44
Study 27049457 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 three-times-weekly (MTD 150 mg)
Number of subjects: 44
Study 27049457 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 5/2 dosing schedule (MTD 60 mg)
Number of subjects: 44
Study 27049457 — intervention group
Group type: EXPERIMENTAL
Intervention: CUDC-907 (overall)
Number of subjects: 44
Study 27049487 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 120 mg q.d. (12 or 24 weeks) with PegIFN/RBV
Number of subjects: 0
Study 27049487 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir 240 mg q.d. (12 weeks) with PegIFN/RBV
Number of subjects: 0
Study 27049487 — intervention group
Group type: COMPARATOR
Intervention: Placebo with PegIFN/RBV
Number of subjects: 0
Study 27049694 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with excess adiposity (BMI ≥25.0 kg/m2)
Number of subjects: 2619
Study 27049694 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with anaemia (Hb <120 g/l)
Number of subjects: 2619
Study 27049694 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with both overweight and anaemia
Number of subjects: 2619
Study 27049694 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender inequalities in overweight adjusted for covariates
Number of subjects: 2619
Study 27049694 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender inequality in anaemia or overweight and anaemia
Number of subjects: 2619
Study 27050437 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) defined as Apnea-Hypopnea Index (AHI) ≥10
Number of subjects: 123
Study 27050437 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI ≥30)
Number of subjects: 123
Study 27050437 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA severity defined according to AHI quartile
Number of subjects: 123
Study 27050437 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA
Number of subjects: 123
Study 27050437 — intervention group
Group type: EXPERIMENTAL
Intervention: OSA severity
Number of subjects: 123
Study 27050823 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighed Blood Loss (WBL)
Number of subjects: 1140
Study 27050823 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based methods of PPH diagnosis
Number of subjects: 1140
Study 27051260 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch PAT-100 portable monitoring device for full-night unattended polysomnography
Number of subjects: 19
Study 27052654 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 + docetaxel (MBC)
Number of subjects: 98
Study 27052654 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 + docetaxel (LABC)
Number of subjects: 98
Study 27052654 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 + docetaxel + pertuzumab (LABC)
Number of subjects: 98
Study 27052654 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 + docetaxel ± pertuzumab
Number of subjects: 98
Study 27052658 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg once a day) plus prednisone (5 mg twice a day)
Number of subjects: 30
Study 27053275 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (AP)
Number of subjects: 200
Study 27053291 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer testing
Number of subjects: 524
Study 27053291 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer testing with additional factors (sex, age, Katz ADL)
Number of subjects: 524
Study 27053381 — intervention group
Group type: COMPARATOR
Intervention: Indian neonates
Number of subjects: 333
Study 27053381 — intervention group
Group type: COMPARATOR
Intervention: Malay neonates
Number of subjects: 333
Study 27053381 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese neonates
Number of subjects: 333
Study 27053961 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral evaluation of cognitive function, adaptive function, autism symptoms, and problem behaviors.
Number of subjects: 33
Study 27053961 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral evaluation of aggressive behavior.
Number of subjects: 33
Study 27053961 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of autism diagnostic instruments.
Number of subjects: 33
Study 27053961 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum and CSF 7-DHC and 8-DHC with functioning.
Number of subjects: 33
Study 27053961 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental milestones evaluation.
Number of subjects: 33
Study 27053961 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF cholesterol correlation with cognitive or adaptive functioning.
Number of subjects: 33
Study 27054029 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) involving 3 cycles of 5 min of lower limb occlusion with a pneumatic tourniquet inflated to 200 mmHg alternating with 5 min of reperfusion.
Number of subjects: 0
Study 27054029 — intervention group
Group type: COMPARATOR
Intervention: Sham control involving the cuff placed on the thigh without inflation.
Number of subjects: 0
Study 27054272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 1004
Study 27054272 — intervention group
Group type: COMPARATOR
Intervention: Other AED
Number of subjects: 1004
Study 27054297 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral glucose tolerance test (OGTT)
Number of subjects: 962
Study 27054341 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group counseling intervention (7 sessions, 2 hours each)
Number of subjects: 0
Study 27054919 — intervention group
Group type: EXPERIMENTAL
Intervention: EZH2 expression levels
Number of subjects: 0
Study 27054919 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferation rate
Number of subjects: 0
Study 27055247 — intervention group
Group type: EXPERIMENTAL
Intervention: SMT C1100 (50 mg/kg on Days 1 and 11, 50 mg/kg bid on Days 2 to 10)
Number of subjects: 12
Study 27055247 — intervention group
Group type: EXPERIMENTAL
Intervention: SMT C1100 (100 mg/kg on Days 1 and 11, 100 mg/kg bid on Days 2 to 10)
Number of subjects: 12
Study 27055247 — intervention group
Group type: EXPERIMENTAL
Intervention: SMT C1100 (100 mg/kg on Days 1 and 11, 100 mg/kg tid on Days 2 to 10)
Number of subjects: 12
Study 27055466 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected 2010-2012 hs-cTnT lots
Number of subjects: 857
Study 27055466 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalculated 2010-2012 hs-cTnT values
Number of subjects: 857
Study 27055466 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected assay (re-measured in 2013)
Number of subjects: 857
Study 27055466 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected lots using ESC 0 h/1 h algorithm
Number of subjects: 857
Study 27055466 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected lots using ESC 0 h/1 h algorithm
Number of subjects: 857
Study 27055731 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX plus PF-04136309 (500 mg twice daily)
Number of subjects: 47
Study 27055731 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRINOX alone
Number of subjects: 47
Study 27055731 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX plus PF-04136309
Number of subjects: 47
Study 27055745 — intervention group
Group type: COMPARATOR
Intervention: Model 2 with biomechanical CT metrics
Number of subjects: 0
Study 27055745 — intervention group
Group type: EXPERIMENTAL
Intervention: Jacobian mean
Number of subjects: 0
Study 27055745 — intervention group
Group type: EXPERIMENTAL
Intervention: Coefficient of variation (CV) of Jacobian
Number of subjects: 0
Study 27055745 — intervention group
Group type: EXPERIMENTAL
Intervention: CV of strain
Number of subjects: 0
Study 27055830 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial Cryobiopsy (Cryo-TBB)
Number of subjects: 51
Study 27055830 — intervention group
Group type: COMPARATOR
Intervention: Surgical lung biopsy (SLB)
Number of subjects: 51
Study 27055851 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Dietary Inflammatory Index (DII)
Number of subjects: 3080
Study 27055851 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DII
Number of subjects: 3080
Study 27055915 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic and pharmacological manipulation of the unfolded protein response (UPR) in mouse models of myelinating glia disorders.
Number of subjects: 0
Study 27056179 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant 3D CRT for breast cancer
Number of subjects: 120
Study 27056586 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 0.3 mg/kg
Number of subjects: 0
Study 27056586 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg
Number of subjects: 0
Study 27056586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27057326 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula containing L. reuteri, GOS (5.50 g/L), and FOS (0.36 g/L)
Number of subjects: 140
Study 27057326 — intervention group
Group type: COMPARATOR
Intervention: Control formula containing only L. reuteri
Number of subjects: 140
Study 27057332 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping for about 5 minutes
Number of subjects: 20
Study 27057335 — intervention group
Group type: EXPERIMENTAL
Intervention: Polluting fuels (kerosene, charcoal, coal, wood, straw, crop waste, dung)
Number of subjects: 65912
Study 27057335 — intervention group
Group type: COMPARATOR
Intervention: Clean fuels (electricity, LPG, natural gas, biogas)
Number of subjects: 65912
Study 27057414 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 44
Study 27057414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27058744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hypertonic dextrose injections (12.5% dextrose, 10 mL, four to six monthly injections)
Number of subjects: 6
Study 27058874 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic endovascular cooling to a target of 34.5-35°C, initiated 60-90 min before CEA and maintained during CEA
Number of subjects: 7
Study 27059507 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptives
Number of subjects: 987
Study 27059507 — intervention group
Group type: COMPARATOR
Intervention: No medical contraindication
Number of subjects: 987